297 related articles for article (PubMed ID: 11724962)
1. Complement activation in factor D-deficient mice.
Xu Y; Ma M; Ippolito GC; Schroeder HW; Carroll MC; Volanakis JE
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14577-82. PubMed ID: 11724962
[TBL] [Abstract][Full Text] [Related]
2. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
3. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
4. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia.
Mueller-Ortiz SL; Drouin SM; Wetsel RA
Infect Immun; 2004 May; 72(5):2899-906. PubMed ID: 15102802
[TBL] [Abstract][Full Text] [Related]
5. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
6. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
[TBL] [Abstract][Full Text] [Related]
7. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
8. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
Fu Q; McPhie P; Gowda DC
Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
[TBL] [Abstract][Full Text] [Related]
9. The cobra complement system: I. The alternative pathway of activation.
Vogel CW; Müller-Eberhard HJ
Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
[TBL] [Abstract][Full Text] [Related]
10. Factor D of the alternative pathway of bovine complement: isolation and characterization.
Menger M; Aston WP
Vet Immunol Immunopathol; 1984 Oct; 7(3-4):325-36. PubMed ID: 6568787
[TBL] [Abstract][Full Text] [Related]
11. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
Hodgetts SI; Grounds MD
Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
[TBL] [Abstract][Full Text] [Related]
12. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
13. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS
Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043
[TBL] [Abstract][Full Text] [Related]
14. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection.
Ren B; McCrory MA; Pass C; Bullard DC; Ballantyne CM; Xu Y; Briles DE; Szalai AJ
J Immunol; 2004 Dec; 173(12):7506-12. PubMed ID: 15585877
[TBL] [Abstract][Full Text] [Related]
15. Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.
van Dam AP; Hack CE
Immunology; 1987 Jun; 61(2):105-10. PubMed ID: 3596635
[TBL] [Abstract][Full Text] [Related]
16. The role of complement activation in tumour necrosis factor-induced lethal hepatitis.
Libert C; Wielockx B; Grijalba B; Van Molle W; Kremmer E; Colten HR; Fiers W; Brouckaert P
Cytokine; 1999 Aug; 11(8):617-25. PubMed ID: 10433810
[TBL] [Abstract][Full Text] [Related]
17. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
Nilsson-Ekdahl K; Nilsson B
Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
[TBL] [Abstract][Full Text] [Related]
19. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor.
O'Keefe MC; Caporale LH; Vogel CW
J Biol Chem; 1988 Sep; 263(25):12690-7. PubMed ID: 3045125
[TBL] [Abstract][Full Text] [Related]
20. New synthetic inhibitor to the alternative complement pathway.
Ikari N; Sakai Y; Hitomi Y; Fujii S
Immunology; 1983 Aug; 49(4):685-91. PubMed ID: 6553561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
